Anti-COX2 / Cyclooxygenase 2 antibody [EPR12012],Abcam,AB179800

Target data Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20 : 4(n-6)), with a particular role in the inflammatory response (PubMed : 11939906, PubMed : 16373578, PubMed : 19540099, PubMed : 22942274, PubMed : 26859324, PubMed : 27226593, PubMed : 7592599, PubMed : 7947975, PubMed : 9261177). The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes (PubMed : 16373578, PubMed : 22942274, PubMed : 26859324, PubMed : 27226593, PubMed : 7592599, PubMed : 7947975, PubMed : 9261177). This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed : 16373578, PubMed : 22942274, PubMed : 26859324, PubMed : 27226593, PubMed : 7592599, PubMed : 7947975, PubMed : 9261177). Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20 : 3(n-6)) and eicosapentaenoate (EPA, C20 : 5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins (PubMed : 11939906, PubMed : 19540099). In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids (PubMed : 27642067). Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response (PubMed : 22942274). Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols (PubMed : 11034610, PubMed : 11192938, PubMed : 9048568, PubMed : 9261177). Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation (PubMed : 12391014). Metabolizes docosahexaenoate (DHA, C22 : 6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) (PubMed : 12391014). As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20 : 5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 (PubMed : 21206090). In vascular endothelial cells, converts docosapentaenoate (DPA, C22 : 5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection (PubMed : 26236990). In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) (PubMed : 22068350, PubMed : 26282205). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18 : 2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity). See full target information PTGS2